Get the latest delivered to your inbox
Privacy Policy

Now Reading

Gilead’s Ambition: To Help End the HIV Epidemic

Gilead’s Ambition: To Help End the HIV Epidemic

Published 11-29-23

Submitted by Gilead Sciences

Three people seated on a stage each with a microphone.

"At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone," shared Janet Dorling, Senior Vice President, Intercontinental Region and Global Patient Solutions.

Through our community partnerships in low-and-middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.

The panel discussion at the recent World Health Summit also featured leaders from The Global Network of People Living with HIV (GNP+), UNAIDS and PEPFAR.

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Originally published by Gilead Sciences

Gilead Sciences Logo

Gilead Sciences

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

More from Gilead Sciences

Join today and get the latest delivered to your inbox